PDF(Pubmed)
Abstract：
UNASSIGNED: The effect of combining prone ventilation with traditional Chinese medicine on severe pneumonia remains unclear.
UNASSIGNED: To evaluate the effect of Fu Zheng Jie Du Formula (FZJDF) combined with prone ventilation on clinical outcomes in patients with severe pneumonia.
UNASSIGNED: This single-center retrospective cohort study included 188 severe pneumonia patients admitted to the ICU from January 2022 to December 2023. Patients were divided into an FZJD group (receiving FZJDF for 7 days plus prone ventilation) and a non-FZJD group (prone ventilation only). Propensity score matching (PSM) was performed to balance baseline characteristics. The primary outcome was the change in PaO2/FiO2 ratio after treatment. Secondary outcomes included 28-day mortality, duration of mechanical ventilation, length of ICU stay, PaCO2, lactic acid levels, APACHE II score, SOFA score, Chinese Medicine Score, inflammatory markers, and time to symptom resolution.
UNASSIGNED: After PSM, 32 patients were included in each group. Compared to the non-FZJD group, the FZJD group showed significantly higher PaO2/FiO2 ratios, lower PaCO2, and lower lactic acid levels after treatment (p < 0.05 for all). The FZJD group also had significantly lower APACHE II scores, SOFA scores, Chinese Medicine Scores, and levels of WBC, PCT, hs-CRP, and IL-6 (p < 0.05 for all). Time to symptom resolution, including duration of mechanical ventilation, length of ICU stay, time to fever resolution, time to cough resolution, and time to resolution of pulmonary rales, was significantly shorter in the FZJD group (p < 0.05 for all). There was no significant difference in 28-day mortality between the two groups.
UNASSIGNED: FZJDF as an adjuvant therapy to prone ventilation can improve oxygenation and other clinical outcomes in severe pneumonia patients. Prospective studies are warranted to validate these findings.
UNASSIGNED: To evaluate the effect of Fu Zheng Jie Du Formula (FZJDF) combined with prone ventilation on clinical outcomes in patients with severe pneumonia.
UNASSIGNED: This single-center retrospective cohort study included 188 severe pneumonia patients admitted to the ICU from January 2022 to December 2023. Patients were divided into an FZJD group (receiving FZJDF for 7 days plus prone ventilation) and a non-FZJD group (prone ventilation only). Propensity score matching (PSM) was performed to balance baseline characteristics. The primary outcome was the change in PaO2/FiO2 ratio after treatment. Secondary outcomes included 28-day mortality, duration of mechanical ventilation, length of ICU stay, PaCO2, lactic acid levels, APACHE II score, SOFA score, Chinese Medicine Score, inflammatory markers, and time to symptom resolution.
UNASSIGNED: After PSM, 32 patients were included in each group. Compared to the non-FZJD group, the FZJD group showed significantly higher PaO2/FiO2 ratios, lower PaCO2, and lower lactic acid levels after treatment (p < 0.05 for all). The FZJD group also had significantly lower APACHE II scores, SOFA scores, Chinese Medicine Scores, and levels of WBC, PCT, hs-CRP, and IL-6 (p < 0.05 for all). Time to symptom resolution, including duration of mechanical ventilation, length of ICU stay, time to fever resolution, time to cough resolution, and time to resolution of pulmonary rales, was significantly shorter in the FZJD group (p < 0.05 for all). There was no significant difference in 28-day mortality between the two groups.
UNASSIGNED: FZJDF as an adjuvant therapy to prone ventilation can improve oxygenation and other clinical outcomes in severe pneumonia patients. Prospective studies are warranted to validate these findings.
摘要：
■易感通气与中药联合治疗重症肺炎的效果尚不清楚。
■评价扶正解毒方(FZJDF)联合俯卧位通气对重症肺炎患者临床预后的影响。
■这项单中心回顾性队列研究包括2022年1月至2023年12月入住ICU的188名重症肺炎患者。患者分为FZJD组（接受FZJDF7天加俯卧位通气）和非FZJD组（仅俯卧位通气）。进行倾向评分匹配(PSM)以平衡基线特征。主要结果是治疗后PaO2/FiO2比值的变化。次要结果包括28天死亡率，机械通气的持续时间，ICU住院时间,PaCO2，乳酸水平，APACHEII得分,SOFA得分,中医评分,炎症标志物，和症状解决的时间。
■PSM后，每组32例。与非FZJD组相比，FZJD组显示显著较高的PaO2/FiO2比值，治疗后PaCO2降低，乳酸水平降低（均p<0.05）。FZJD组的APACHEII评分也明显降低，SOFA分数,中医成绩,和白细胞水平，PCT,hs-CRP,和IL-6(全部p<0.05)。症状解决时间，包括机械通气的持续时间，ICU住院时间,发烧时间决议，咳嗽消退的时间，以及解决肺部啰音的时间，FZJD组明显较短（均p<0.05）。两组之间的28天死亡率没有显着差异。
■FZJDF作为俯卧通气的辅助治疗可以改善重症肺炎患者的氧合和其他临床结局。有必要进行前瞻性研究以验证这些发现。
■评价扶正解毒方(FZJDF)联合俯卧位通气对重症肺炎患者临床预后的影响。
■这项单中心回顾性队列研究包括2022年1月至2023年12月入住ICU的188名重症肺炎患者。患者分为FZJD组（接受FZJDF7天加俯卧位通气）和非FZJD组（仅俯卧位通气）。进行倾向评分匹配(PSM)以平衡基线特征。主要结果是治疗后PaO2/FiO2比值的变化。次要结果包括28天死亡率，机械通气的持续时间，ICU住院时间,PaCO2，乳酸水平，APACHEII得分,SOFA得分,中医评分,炎症标志物，和症状解决的时间。
■PSM后，每组32例。与非FZJD组相比，FZJD组显示显著较高的PaO2/FiO2比值，治疗后PaCO2降低，乳酸水平降低（均p<0.05）。FZJD组的APACHEII评分也明显降低，SOFA分数,中医成绩,和白细胞水平，PCT,hs-CRP,和IL-6(全部p<0.05)。症状解决时间，包括机械通气的持续时间，ICU住院时间,发烧时间决议，咳嗽消退的时间，以及解决肺部啰音的时间，FZJD组明显较短（均p<0.05）。两组之间的28天死亡率没有显着差异。
■FZJDF作为俯卧通气的辅助治疗可以改善重症肺炎患者的氧合和其他临床结局。有必要进行前瞻性研究以验证这些发现。
